Shek, Felix H <br/><br/>
Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.  [electronic resource] 

 -  Cellular oncology (Dordrecht, Netherlands)  Oct 2017 
 - 443-456 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2211-3436 
<br/><br/><label>Standard No.: </label>10.1007/s13402-017-0332-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cadherins--genetics<br/>Carcinoma, Hepatocellular--genetics<br/>Cell Line<br/>Cell Line, Tumor<br/>Cohort Studies<br/>Gene Expression Profiling--methods<br/>Gene Expression Regulation, Neoplastic<br/>Hep G2 Cells<br/>Humans<br/>Liver Neoplasms--genetics<br/>RNA Interference<br/>Signal Transduction--genetics<br/>Trypsin Inhibitor, Kazal Pancreatic--blood<br/>beta Catenin--genetics